Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19
Bodro, Marta (Hospital Clínic i Provincial de Barcelona)
Cofan, Frederic (Hospital Clínic i Provincial de Barcelona)
Ríos, José (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública)
Herrera, Sabina (Hospital Clínic i Provincial de Barcelona)
Linares, Laura (Hospital Clínic i Provincial de Barcelona)
Marcos, María Ángeles (Hospital Clínic i Provincial de Barcelona)
Soriano, A (Hospital Clínic i Provincial de Barcelona)
Moreno Camacho, Asunción (Hospital Clínic i Provincial de Barcelona)
Diekmann, Fritz (Hospital Clínic i Provincial de Barcelona)

Fecha:	2021
Resumen:	In the context of the coronavirus disease 2019 (COVID-19) pandemic, we aimed to evaluate the impact of anti-cytokine therapies (AT) in kidney transplant recipients requiring hospitalization due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This is an observational retrospective study, which included patients from March to May 2020. An inverse probability of treatment weighting from a propensity score to receive AT was used in all statistical analyses, and we applied a bootstrap procedure in order to calculate an estimation of the 2. 5th and 97. 5th percentiles of odds ratio (OR). outcomes were measured using an ordinal scale determination (OSD). A total of 33 kidney recipients required hospitalization and 54% of them received at least one AT, mainly tocilizumab (42%), followed by anakinra (12%). There was no statistical effect in terms of intensive care unit (ICU) admission, respiratory secondary infections (35% vs. 7%) or mortality (16% vs. 13%) comparing patients that received AT with those who did not. Nevertheless, patients who received AT presented better outcomes during hospitalization in terms of OSD ≥5 ((OR 0. 31; 2. 5th, 97. 5th percentiles (0. 10; 0. 72)). These analyses indicate, as a plausible hypothesis, that the use of AT in kidney transplant recipients presenting with COVID-19 could be beneficial, even though multicenter randomized control trials using these therapies in transplanted patients are needed.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	COVID-19 ; Kidney transplantation ; Anti-cytokine therapy ; Mortality ; Infection
Publicado en:	Journal of clinical medicine, Vol. 10 Núm. 8 (2021) , p. 1551, ISSN 2077-0383

DOI: 10.3390/jcm10081551
PMID: 33917093

10 p, 417.3 KB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados